- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04049539
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To demonstrate the safety and estimate the efficacy of liposome-encapsulated daunorubicin-cytarabine (Vyxeos) in acute myeloid leukemia (AML) patients who have failed to achieve a hypocellular marrow after an initial course of 7+3.
SECONDARY AND/OR EXPLORATORY OBJECTIVES:
I. Determination of rate of morphologic leukemia-free state (MLFS). II. Determination of progression-free survival (PFS), and overall survival (OS) at 2 years.
III. Mass cytometric measurement relative clearance of quiescent leukemia stem/repopulating cells (LSCs) and blasts as compared to the same patient's preceding cycle of 7+3 and to a separate control population receiving re-induction with traditional 7+3.
IIIa. Measurement of blast cell cycle fraction before and after Vyxeos treatment.
IIIb. Relative clearance immunophenotypically abnormal blast and stem cells after Vyxeos.
IIIc. Comparison of efficacy of blast cell and LSC elimination in patients receiving Vyxeos re-induction compared to similar blast cells and LSCs in patients receiving standard 7+3 or 5+2 re-induction.
OUTLINE:
Within 14-33 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine intravenously (IV) over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up weekly for 60 days, then at least monthly for 2 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: The Ohio State University Comprehensive Cancer Center
- Phone Number: 1-800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Comprehensive Cancer Center
-
Principal Investigator:
- Brian Jonas, MD, PhD
-
Contact:
- Brian Jonas, MD, PhD
- Phone Number: 916-734-3772
- Email: bajonas@ucdavis.edu
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Gregory K. Behbehani, MD, PhD
- Email: gregory.behbehani@osumc.edu
-
Contact:
- Ana Swatzell
- Phone Number: 614-685-9573
- Email: adriana.swatzell@osumc.edu
-
Principal Investigator:
- Gregory K. Behbehani, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject or their legal guardian must be able to provide written informed consent
- Patients must have a diagnosis of acute myeloid leukemia
- Patients must have received standard continuous infusion cytarabine and daunorubicin (cytarabine 100-200 mg/m^2 by continuous infusion on days 1-7 and daunorubicin 45-90 mg/m^2 on days 1-3) within the 14-33 days prior to starting trial treatment and have documented persistent disease (13-29 days from the start of 7+3 treatment). Patients who have received a 7+3 regimen utilizing idarubicin (12 mg/m^2 on days 1-3) in place of daunorubicin may enroll. Persistent disease will be defined as bone marrow cellularity of > 10-20% and bone marrow blast percentage of > 5-10% or clear evidence of immunophenotypically aberrant leukemia cells in the bone marrow. The final determination of persistent AML will be made by the treating physician, but must meet National Comprehensive Cancer Network (NCCN) criteria for persistent disease. Enrollment of patients with less than 20% cellularity or less than 10% blasts will require approval of the principal investigator. Patients who received concomitant treatment with another targeted therapy for AML (e.g. midostaurin) during initial induction may enroll, but will not continue to receive this treatment during Vyxeos treatment
- Patients must be deemed by the treating physician to be unlikely to achieve complete response (CR) without further therapy
- Patients must be deemed by the treating physician to be able to tolerate intensive chemotherapy (similar to 7+3 chemotherapy)
- Normal left ventricular ejection fraction (>= 50% by echocardiography or multi-gated acquisition radionuclide angiocardiography [MUGA]) and lifetime daunorubicin dose of less than 418 mg/m^2 (including recent course of 7+3)
- Eastern Cooperative Oncology Group (ECOG) functional status of 0, 1, or 2
- Aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN) for the local laboratory
- Alanine aminotransferase (ALT) < 5 x ULN for the local laboratory
- Total bilirubin < 1.5 x ULN (except for patients with known Gilbert?s syndrome) for the local laboratory
- Calculated creatinine clearance (according to the Cockcroft-Gault equation) > 40 mL/min OR serum creatinine < 1.5 x the ULN for the local laboratory
- Female patients of childbearing potential must agree to use two forms of contraception from screening visit until 6 months following the last dose of study treatment. Female patients must have a documented negative pregnancy test
- Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use two forms of contraception from screening visit until 90 days until the last dose of study treatment. They must also refrain from sperm donation from screening visit until 90 days following the last dose of study treatment
Exclusion Criteria:
- Acute promyelocytic leukemia (or M3 AML)
- Patients known to have core binding factor AML (defined as presence of t(8;21), inv(16), or other cytogenetically equivalent abnormalities)
- Patients known to have inactivating mutations of TP53 or evidence of an absence of p53 protein activity as indicated by a monosomal karyotype. Monosomal karyotype will be defined as two or more monosomies (loss of an entire chromosome or the entire long arm of a chromosome [such as 7q-]) or a single monosomy in the setting of a complex karyotype. Patients with a complex karyotype without a monosomy are eligible to enroll
- Patients that the treating physician does not feel are able to tolerate intensive chemotherapy
- History of serious (>= grade 3) hypersensitivity reaction to cytarabine, daunorubicin, or any component of the formulation
- Known Wilson's disease or other symptomatic abnormality of copper metabolism (laboratory screening is not required in the absence of clinical or historical evidence of Wilson's disease or other problems of copper metabolism)
- Total lifetime daunorubicin dose of more than 418 mg/m^2 (including recent course of 7+3) or equivalent total doses of other anthracycline medications
- Pregnancy or inability to use highly effective method of contraception for 6 months following last dose of Vyxeos. Potentially fertile patients must have documented negative serum pregnancy test. Breastfeeding should be avoided for at least 14 days after the last dose Vyxeos
- Patients with uncontrolled infection shall not be enrolled until infection is treated and brought under control. As infection is a common feature of AML, patients with active infections are permitted to enroll provided that the infection is under control
- Patients who have received an investigational agent (for any indication) within 5 half-lives of the agent and until toxicity from this has resolved to grade 1 or less; if the half-life of the agent is unknown, patients must wait 4 weeks prior to first dose of study treatment. An investigational agent is one for which there is no approved indication by the United States (US) Food and Drug Administration (FDA)
- Patients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up
- Any other significant medical condition, including psychiatric illness or laboratory abnormality, that would preclude the patient participating in the trial or would confound the interpretation of the results of the trial
- Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Other malignancy currently requiring active therapy (except minor surgery for non-melanoma skin cancer and for hormonal/anti-hormonal treatment, e.g. in prostate or breast cancer)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (liposome-encapsulated daunorubicin-cytarabine)
Within 14-33 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 60 days
|
Will be measured by the time to count recovery, incidence of symptomatic cardiac dysfunction, incidence of hepatic or renal toxicity, incidence of severe hemorrhage, and incidence of severe infection.
Will be summarized by National Cancer Institute Common Terminology Criteria for Adverse Events version 4, and frequency counts will be tabulated with a focus on severe (grade 3+) adverse events and toxicities that are deemed at least possibly related to study treatment.
The incidence of specific toxicities will be calculated as the proportion of patients experience these toxicities over all patients who receive any study drug.
|
Up to 60 days
|
Calculation rate of complete response (CR) and complete response with incomplete hematologic recovery (CRi)
Time Frame: Up to 2 years
|
CR and CRi rate will be defined as the proportion of patients who achieve CR or CRi over all evaluable patients.
The rates will be provided with 95% binomial confidence intervals.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Up to 2 years
|
Will be calculated by the method of Kaplan-Meier, with the 2-year estimate provided with 95% confidence interval.
|
Up to 2 years
|
Overall survival
Time Frame: From the date of the first dose of study treatment to death from any cause, up to 2 years
|
Will be calculated by the method of Kaplan-Meier, with the 2-year estimate provided with 95% confidence interval.
|
From the date of the first dose of study treatment to death from any cause, up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of blast cell cycle fraction
Time Frame: Baseline up to day 42
|
Will be exploratory in nature with graphical methods and descriptive statistics provided to gather preliminary information.
Nonparametric method such Mann-Whitney U test will be utilized to compare pre and post-treatment data, and box plot or spaghetti plot will be presented to help visualize the trend of change.
|
Baseline up to day 42
|
Relative clearance immunophenotypically abnormal blast and stem cells
Time Frame: Up to day 42
|
Will be exploratory in nature with graphical methods and descriptive statistics provided to gather preliminary information.
Nonparametric method such Mann-Whitney U test will be utilized to compare pre and post-treatment data, and box plot or spaghetti plot will be presented to help visualize the trend of change.
|
Up to day 42
|
Efficacy of blast cell and leukemia stem/repopulating cell (LSC) elimination
Time Frame: Up to day 42
|
Will compare the efficacy of blast cell and LSC elimination in patients receiving Vyxeos re-induction compared to similar blast cells and LSCs in patients receiving standard 7+3 or 5+2 re-induction.
Will be exploratory in nature with graphical methods and descriptive statistics provided to gather preliminary information.
Nonparametric method such Mann-Whitney U test will be utilized to compare pre and post-treatment data, and box plot or spaghetti plot will be presented to help visualize the trend of change.
|
Up to day 42
|
Number of patients proceeding to stem cell transplantation following Vyxeos treatment
Time Frame: Up to 2 years
|
Will be measured and is exploratory in nature.
It will be analyzed with descriptive statistics to gather preliminary information and compared to historical controls.
|
Up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gregory K Behbehani, MD, PhD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cytarabine
- Daunorubicin
Other Study ID Numbers
- OSU-19060
- NCI-2019-04724 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Acute Myeloid Leukemia
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
Shanghai Jiao Tong University School of MedicineRecruitingRefractory Acute Myeloid LeukemiaChina
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Association for Training, Education, and Research...CompletedRefractory Acute Myeloid LeukemiaFrance
-
Michael BoyiadzisMerck Sharp & Dohme LLCWithdrawnRefractory Acute Myeloid LeukemiaUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Liposome-encapsulated Daunorubicin-Cytarabine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Roswell Park Cancer InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene MutationsUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated CellsUnited States
-
Fred Hutchinson Cancer CenterJazz PharmaceuticalsTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Multilineage Dysplasia | Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States
-
Ohio State University Comprehensive Cancer CenterIncyte Corporation; Jazz PharmaceuticalsRecruitingPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Secondary Acute Myeloid Leukemia | Myeloproliferative NeoplasmUnited States